| 1981 |
Business founded by Joel C. Bradley, Ph.D., MIT, to provide isotopically labeled
research compounds and NMR solvents to the new and developing commercial market for
stable isotope labeled compounds. |
| 1983 |
Moved from Cambridge, Massachusetts to larger laboratory space in Woburn,
Massachusetts to accommodate the expanding staff and laboratories. |
| 1985 |
Established international presence with first major Sales Representative in Europe. |
| 1986 |
Founded CIL Japan and established offices in Osaka and Tokyo. |
| 1987 |
Raised expansion capital in an initial public offering on the Securities market in the
United Kingdom. |
|
Construction begins on $3.2 million 13C separation facility in Xenia, Ohio, the
largest facility of its kind at the time. |
| 1988 |
Acquired the stable isotope division of ICN Biomedicals, a competitor in stable
isotope research products. |
|
Established the first field sales force in the industry in the United States. |
| 1990 |
Invested in the first super conducting FT/NMR spectrometer to match the quality
assurance capabilities of our best customers. |
| 1992 |
Achieved $10 Million in sales. |
|
Purchased a second super conducting FT/NMR spectrometer. |
| 1993 |
Acquired the assets of MSD Isotopes from Merck Frost of Canada, a major competitor
and the oldest stable isotope company in the industry. |
|
Awarded $100,000 in 13C products in the first CIL Research Grant Program to promote
novel applications of 13C by the research community. |
| 1994 |
Built state-of-the-art laboratories at our new site in Andover, Massachusetts to
bring all laboratory operations under one roof and to provide space for expansion. |
|
Implemented GMP programs. |
| 1995 |
Awarded over $100,000 in 13C & D compounds in a second CIL Research Grant Program. |
| 1996 |
Significant expansion of production capacity of 13C separation facility in Ohio to
meet the growing demand, again the largest facility of its kind at the time. |
| 1998 |
Corporate merger with Otsuka Pharmaceuticals to facilitate a joint development of
certain medical diagnostic products. CIL continues operations with the same
executives and key managers and with an independent Board of Directors. |
| 1999 |
Construction begins on $6 Million 18O separation facility in Xenia, Ohio to meet the
rapidly expanding needs of the Positron Emission Tomography (PET) and the metabolism research markets,
again the largest in the world. |
| 2001 |
Completed construction on 18O separation facility. |
|
Established close partnership with Euriso-top S.A |
